Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.

Oncotarget - 7 Mar 2017

Geißler Anna-Lena, Geißler Miriam, Kottmann Daniel, Lutz Lisa, Fichter Christiane D, Fritsch Ralph, Weddeling Britta, Makowiec Frank, Werner Martin, Lassmann Silke

Abstract excerpt

EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Caco-2 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cadherins

Share to Cetuximab

Share to Class I Phosphatidylinositol 3-Kinases

Share to HCT116 Cells

Share to HT29 Cells

Share to Panitumumab

Source

Open in PubMed Open full text

Identifiers

PMID: 28199979
DOI: 10.18632/oncotarget.15211
PMCID: PMC5370031

Genes

EGFR
ATM

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.PMID 28199979Read ↗

Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas.Semantic proximity Read ↗

Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinoma.Semantic proximity Read ↗

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

Pathologic Complete Response in Patient With ATM Mutation After Neoadjuvant FOLFOXIRI Plus Panitumumab Therapy for Locally Advanced Colon Cancer: A Case Report.Semantic proximity Read ↗

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.Semantic proximity Read ↗

Markers of resistance to anti-EGFR therapy in colorectal cancer.Semantic proximity Read ↗

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature.Semantic proximity Read ↗

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.Semantic proximity Read ↗

Epidermal growth factor receptor in CRC patients in the era of the RAS.Semantic proximity Read ↗

Prognostic impact of ATM mutations in patients with metastatic colorectal cancerSemantic proximity Read ↗

Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patientsSemantic proximity Read ↗

Loss of expression of the double strand break repair protein ATM is associated with worse prognosis in colorectal cancer and loss of Ku70 expression is associated with CIN.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.